The financial and social impact of thalassemia and its treatment in Iran

Pharmaceutical Sciences

Volumn 18, Issue 3, 2012, Pages 171-176

  Sattari, Mohammadreza ^a   Sheykhi, Dorna ^b   Nikanfar, Alireza ^a   Pourfeizi, Abasali Hosseyn ^a   Nazari, Maryam ^c   Dolatkhah, Roya ^a   Mashayekhi, Simin ^a,b  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cost; Economy; Iran; Iron chelating therapy; Thalassemia

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; BLOOD TRANSFUSION; ECONOMIC ASPECT; FEMALE; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; IRAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PRODUCTIVITY; SOCIAL ASPECT; THALASSEMIA; TRAFFIC AND TRANSPORT;

EID: 84903841642     PISSN: 1735403X     EISSN: 23832886     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Walley T. Pharmacoeconomics and Economic Evaluation of Drug Therapies. In: du Souich P, Orme M, Erill S, The IUPHAR Compendium of Basic Principles For Pharmacological Research in Humans. IUPHAR Administrative Office, Department of Pharmacology, College of Medicine, University of California, Irvine. 2004
2. Jelvehgari M, Mashayekhi SO. Demographic and clinical aspects in thalassemic or hemophilic patients referred to pediatric hospitals in Tabriz city, 2004, Iran. Res J Biol Sci 2007;2(5):543-5.
3. Saleh-Gohari N, Bazrafshani M. Distribution of beta-globin gene mutations in thalassemia minor population of kerman province, iran. Iran J Public Health 2010;39(2):69-76.
4. Iran Central bank. Exchange rate: access date 10/06/2009, www.cbi.ir/ExRates/rates-fa.aspx.
5. World Bank Group. Iran; country at a glance http://www.worldbank.org/en/ country/iran
6. Abolghasemi H, Eshghi P, Rahiminejhad S, Hatami S. Evaluation and cost-effectiveness analysis of prevention program of major thalassemia in Sistan-Balouchestan and Fars provinces. Hakim Res J 2006;8(4):8-14.
7. Gallerani M, Cicognani I, Ballardini P, Savelli S, Martinelli L, Ricci A, et al. Average life expectancy of heterozygous beta thalassemic subjects. Haematologica 1990;75(3):224-7. (Pubitemid 20273881)
8. Delea TE, Hagiwara M, Thomas SK, Baladi JF, Phatak PD, Coates TD. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States. Am J Hematol. 2008;83(4):263-70. (Pubitemid 351458002)
9. Scalone L, Mantovani LG, Krol M, Rofail D, Ravera S, Bisconte MG, et al. Costs, quality of life, treatment satisfaction and compliance in patients with beta-thalassemia major undergoing iron chelation therapy: the ITHACA study. Curr Med Res Opin 2008;24(7):1905-17.
10. WHO. World Health Organization. Primary health care approaches for prevention and control of congenital and genetic disorders. Geneva: World Health Organization; 2000.
11. Christianson A, Streetly A, Darr A. Lessons from thalassaemia screening in iran. BMJ 2004;329(7475):1115-7. (Pubitemid 39524765)